Beneficial properties of resveratrol and pterostilbene, a dimethyl ether analog of resveratrol, have attracted increasing interest in recent years. Resveratrol and pterostilbene exhibit many pharmacological similarities and both of them are generally considered to be safe for human consumption. Beyond the structural and general bioactivity similarities between them, large amounts of data are now available to reveal the metabolic fate and pharmacological differences between them. Pterostilbene was found to be more metabolically stable and usually exhibited stronger pharmacological activities than that of resveratrol. As a contribution to clarify and compare aspects like metabolic stability and pharmacokinetics of resveratrol and pterostilbene, as well as explain the pharmacological similarities and differences between them, this review presents and compares recent data on the metabolism and pharmacokinetics of resveratrol and pterostilbene.
Introduction
Resveratrol (trans-3,5,4 0 -trihydroxystilbene, Fig. 1 ) and pterostilbene (trans-3,5-dimethoxy-4 0 -hydroxystilbene, Fig. 2 ) are natural polyphenolic phytoalexins produced by a variety of plants with resveratrol as the precursor of pterostilbene [1] [2] [3] . Structurally, pterostilbene is a dimethyl ether analog of resveratrol. Resveratrol and pterostilbene exhibit many pharmacological similarities including analgesia [4, 5] , antiaging [6] [7] [8] , antidiabetic [9] [10] [11] , anti-inflammation [12] [13] [14] [15] , antiobesity [16] [17] [18] , antioxidation [19] [20] [21] [22] , cholesterol lowering [23] [24] [25] , neuroprotective activities [10, [26] [27] [28] [29] , and so on. As dietary phytophenols, resveratrol, and pterostilbene appeared to be very safe. In a clinical trial study conducted in 40 healthy volunteers, resveratrol proved to be safe after 29 daily doses of 0.5, 1.0, 2.5, and 5.0 g, except the 2.5 and 5.0 g doses caused mild to moderate gastrointestinal symptoms [30] . In experimental animals, 28 daily doses of 50, 150, or 500 mg/kg body weight of pure resveratrol did not cause any adverse effects in rats; similarly, 90 daily dose of 700 mg/kg body weight of pure resveratrol did not induce any adverse effects in rats either [31] . For pterostilbene, a long-term, prospective, randomized, double-blind, placebo-controlled intervention trial was conducted in 80 healthy volunteers for 6-8 weeks, which proved that pterostilbene is generally safe for use in humans at doses up to 250 mg per day [32] .
Beyond the structural and general bioactivity similarities between resveratrol and pterostilbene, in vitro and/or in vivo pharmacological activities of pterostilbene are usually found to be stronger than that of resveratrol [33] [34] [35] [36] [37] [38] . For instance, lowdose of pterostilbene, but not resveratrol, was found to be a potent neuromodulator in aging and Alzheimer's disease [39] . In a previous study [34] , pterostilbene proved to be more potent than resveratrol in preventing azoxymethane-induced colon carcinogenesis. The critical reason could be the presence of the dimethoxy structure in pterostilbene, which creates favorable lipophilicity and hence subsequently increases the membrane permeability as well as its biological potency. Furthermore, methylation of the phenolic hydroxyl may also restrict the glucuronidation and sulfation process of pterostilbene, since pterostilbene provides less conjugating sites compared to resveratrol, resulting in a better metabolic stability.
Over all, compared with resveratrol, pterostilbene may have a better membrane permeability and metabolic stability, which subsequently increased its bioavailability and pharmacokinetic profile as well as its pharmacological activities. However, systematic comparisons of the metabolism and pharmacokinetics of resveratrol and pterostilbene are still sparse.
The purpose of this review was to clarify and compare the metabolic stability and pharmacokinetics aspects of resveratrol and pterostilbene, and to reveal and explain the pharmacological similarities and differences between them, and to provide further support for the use of resveratrol and pterostilbene as pharmacological substances in human medicine.
Metabolism of resveratrol and pterostilbene
Different experimental models and strategies have been used to investigate the metabolism of resveratrol and pterostilbene. It appears that the phase II metabolic enzymes and the gut microbiota play critical roles in their biotransformation; although, their metabolic rate and fate are also dependent on different administration doses, species, genders, tissues, disease status, and so on. Glucuronidation and sulfation pathways of resveratrol and pterostilbene are shown in Figs. 1 and 2.
Glucuronidation of resveratrol and pterostilbene
The UDP-glucuronosyltransferase (UGT) family plays a critical role in the metabolism of both resveratrol and pterostilbene. Resveratrol-3-O-glucuronide and resveratrol-4 0 -O-glucuronide ( Fig. 1) have been reported as the major glucuronides of resveratrol [40, 41] , and pterostilbene-4 0 -O-glucuronide ( Fig. 2 ) was characterized as the dominant glucuronide metabolite of pterostilbene [42] . The UGT enzyme family catalyzes the conjugation of resveratrol with a glucuronic acid moiety at either Glucuronidation and sulfation pathways of resveratrol.
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Wang and Sang the 3 or 4 0 hydroxyl group, subsequently altering the biological properties of resveratrol as well as facilitating its elimination from the body. Previous reports have identified that human liver microsomes (HLMs), which contain high concentrations of most UGT family enzymes, preferentially form the resveratrol-3-O-glucuronide as compared to the resveratrol-4 0 -O-glucuronide [41] . Furthermore, it has been reported that UGT1A1 was mostly responsible for the observed resveratrol-3-O-glucuronidation, while UGT1A9 was primarily responsible for 4 0 -O-glucuronidation. Besides UGT1A1 and 1A9, UGT1A3, 1A6, 1A7, 1A8, and 1A10 also had detectable activity on resveratrol at one or both positions. Interspecies variations in hepatic glucuronidation of resveratrol were found across mice, rats, dogs, and humans [43] . Human UGT1A1 and 1A3 were identified as the two primary UGTs responsible for the glucuronidation of pterostilbene. UGT1A8, 1A9, and 1A10 also had discernable activity but at a significantly lower velocity than UGT1A1 and 1A3 [44] . UGT1A1 and 1A3 preferentially attacked the 3-hydroxyl group of resveratrol, yet they have the highest activity for the glucuronidation of pterostilbene, which can only be attached at the 4 0 -hydroxyl group. Conversely, UGT1A9, which has the highest glucuronidation activity against the 4 0 -hydroxyl of resveratrol, had minimal activity against the 4 0 -hydroxyl group of pterostilbene [44] . In a panel of glucuronidation assays, which were carried out under identical conditions using female HLMs for 1 h, $68% of the resveratrol was conjugated with glucuronic acid, while more than 75% of pterostilbene was still in its unchanged form [44] . Over all, resveratrol proved to be a much better UGT substrate than pterostilbene.
Sulfation of resveratrol and pterostilbene
Sulfation is another major route to eliminate the polyphenols from the human body. 
Microbial biotransformation of resveratrol and pterostilbene
Increasing evidence has shown that gut microbiota have a great effect on the biotransformation of dietary constituents. Besides the glucuronidated and sulfated metabolites of resveratrol, dihydroresveratrol (Fig. 3 ) has been identified as the first microbial-derived metabolite of resveratrol [47] [48] [49] . Recently, two additional microbial-derived metabolites of resveratrol, 3,4 0 -dihydroxy-trans-stilbene and 3,4 0 -dihydroxybibenzyl (lunularin) (Fig. 3 ), were identified in the incubation of resveratrol and human intestinal bacteria, as well as the human fecal samples collected after resveratrol supplement intake [50] .
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Two strains, Slackia equolifaciens and Adlercreutzia equolifaciens, were identified for the primary responsibility of producing the dihydro metabolite of resveratrol [50] . Proposed microbial metabolic pathways of resveratrol are shown in Fig. 3 . The reduction of the carbon-carbon double bond by gut microbiota has also been shown for many other dietary compounds such as isoflavones [51] and hydroxycinnamate [52] . Cleavage of hydroxyl groups plays a role in the microbial transformation of compounds such as lignans, phenolic acids, and bile acids. However, it is still unknown, which gut bacteria are able to produce dehydroxylated metabolites of resveratrol. Furthermore, metabolism of resveratrol by the human gut microbiota shows significant interindividual differences, and gut microbiota collected from 1 of the 7 volunteers failed to reduce the double bond of resveratrol [50] . Interindividual variability in the fecal microbiota composition of humans has been broadly recognized; however, links between dietary phytochemicals, microbiota composition, and health in large populations remain unclear [53] .
Even though pterostilbene has a carbon-carbon double bond as that of resveratrol, no metabolites of pterostilbene with reduced double bond were identified yet. Our previous metabolism study of pterostilbene revealed that aside from glucuronidation and sulfation, hydroxylation and demethylation were the major metabolic routes of pterostilbene [54] . Recently, Sun et al. [55] investigated the metabolites of pterostilbene in CD-1 mouse colonic content and mucosa. After feeding pterostilbenecontaining diet for 3 weeks, pinostilbene (Fig. 4 ) was identified as a major metabolite of pterostilbene in the mouse colon. The level of pinostilbene was found to be approximately equivalent to that of pterostilbene in the colonic mucosa, so the levels of pterostilbene and pinostilbene in the colonic content were about ten times higher than that in the colonic mucosa. Gut microbiota were suspected for the demethylation of pterostilbene, and its potential microbial metabolic pathway is shown in Fig.  4 . It has been well established that microbial demethylases are responsible for the demethylation of flavonols, flavan-3-ols, anthocyanins, lignans, and so on [56] . However, further studies are required to validate this speculation.
Factors influencing the metabolism of resveratrol and pterostilbene
Biotransformation of resveratrol is also dependent on different doses, species, genders, and tissues, as well as disease status. As previously reported [57] , in healthy volunteers, with low doses (5 or 50 mg) of resveratrol, glucuronides are the prominent metabolites present in plasma [58] . When high doses of resveratrol are administrated (!250 mg), the 1-h post-dose plasma concentrations of resveratrol metabolites were significantly higher than that of the parent compound, and metabolite with a sulfate moiety at the 3-hydroxyl position (resveratrol-3-O-sulfate) was identified to be the main metabolite of resveratrol in plasma [59, 60] . Interestingly, metabolite conjugated with a glucuronide and a sulfate moiety (resveratrol sulfate glucuronide) was identified as the main metabolite in plasma samples, which were collected 11-21 h after the last dose, and resveratrol-3-O-sulfate and disulfate were also clearly detected but at much lower concentrations. At high doses, sulfation at the 3-hydroxyl position was hypothesized to be the first step of metabolism, and then glucuronidation or sulfation occurs [61] . However, further studies are required to validate this hypothesis.
The metabolism of resveratrol also differs between humans and other species. For instance, an in vitro microsomal study using liver microsomes from mice, rats, dogs, and humans revealed that rodent liver microsomes had significantly higher glucuronidation activity levels than human and dog liver microsomes [43] . Interesting, a 10-fold increase of resveratrol concentration significantly impaired the formation of the glucuronides in human and dog microsomes. Furthermore, distinct specie-dependent differences were also observed in the stereoselectivity of resveratrol glucuronidation. In human and dog liver microsomes, resveratrol-3-O-glucuronide and resveratrol-4 0 -O-glucuronide were generated at an average ratio of 1:5. However, the formation of resveratrol-4 0 -O-glucuronide in both mouse and rat was significantly reduced (1:45 in mouse; 1:500 in rat). Specie-dependent differences also occurred in the kinetic profiles of resveratrol glucuronidation. In all of the species tested, only the formation of resveratrol-3-O-glucuronide and resveratrol-4 0 -O-glucuronide by dog microsomes showed a kinetic enzyme profile similar to human microsomes, and the use of dogs rather than mice or rats as a model for resveratrol glucuronidation was recommended [43] . Metabolism studies of pterostilbene in different species are warranted.
The impact of gender differences in the glucuronidation of resveratrol and pterostilbene were addressed by Dellinger et al. [44] . HLMs pooled from male (n 5 10) and female (n 5 10) donors were used to investigate the potential differences in glucuronidation profiles, which clearly showed that female HLMs are more efficient than male HLMs in the glucuronidation of both resveratrol and pterostilbene. For pterostilbene, kinetic data demonstrated that although the Michaelis constants (K Ms )
Potential microbial biotransformation pathway of pterostilbene. FIG 4 of male and female HLMs are similar, and female HLMs had a significantly higher maximum rate (V max ) indicating they are capable of much higher catalytic turnover than male HLMs. Similar differences were seen in the formation of resveratrol-3-O-glucuronide where female HLMs exhibited a dramatically increased V max resulting in a higher V max /K MS ratio as compared to male HLMs. Since UGT1A1 has the most activity on resveratrol and pterostilbene, and has the highest expression of any UGT in human livers [44, 62] , the gender difference is most likely attribute to the variation of the UGT1A1 expressions between different human genders despite there being no differences in total UGT1A expression.
Only a few research groups have studied the biotransformation of resveratrol in human tissue samples. Six metabolites of resveratrol were identified in the colon tissues collected from a clinical trial in colorectal cancer patients who received 0.5 or 1.0 g resveratrol caplets daily for eight consecutive days before resection; those metabolites namely being resveratrol-
0 -O-sulfate, and/or resveratrol-3-O-sulfate-5-Oglucuronide), and resveratrol-3,4 0 -O-disulfate ( Fig. 1 ) [63] . Interestingly, in contrast to the pattern in plasma of healthy volunteers, where the sulfate glucuronide is a minor biotransformation product or more commonly, absent, it was a predominant metabolite in tumor samples from 14 out of 20 patients [30] . In human breast cancer cell lines and tissue samples, only resveratrol-3-O-sulfate could be detected [64] . Notably, the formation of resveratrol-3-O-sulfate showed a high degree of inter-individual variation. Resveratrol sulfation was significantly higher in 12 out of 13 breast cancer tissue samples, and these samples showed a 33.5-fold higher formation rate as compared with their nontumor counterparts. In a recent study [65] , resveratrol-3-O-sulfate was determined as the main metabolite of resveratrol in human eye tissues in the conjunctiva, aqueous humor, and vitreous humor, in which the average concentrations of this metabolite were 22.3 nmol/g, 364.9 nM, and 63.0 nM, respectively. At low physiological dose (3-30 lM), resveratrol is rapidly metabolized into its sulfated form in a dose-dependent fashion in human adipocytes, and SULT1A1 was found as the key enzyme in adipocytes responsible for the biotransformation of resveratrol [66] .
In different disease status, for example, significantly greater sulfation of resveratrol occurs in human breast tumor tissue than in adjacent nonmalignant tissue. The observed differences do not correlate with the expression of sulfotransferases responsible for catalyzing resveratrol sulfation, but rather with significantly higher steroid sulfatase mRNA levels [67] .
In our recent study [68] , a prodrug of resveratrol and aspirin, (E)-4-(3,5-dihydroxystyryl)phenyl 2-acetoxybenzoate (RAH), was synthesized, and its metabolic fate in mice was investigated. Our observations indicated that certain amounts of RAH were able to bear the acidic environment of stomach, avoid enzymatic hydrolysis in the small intestine, reach the colon, and then be incorporated into the colon tissue as an intact molecule, thereby contributing its potential chemopreventive properties to the health of colon, like resveratrol reported previously [69] . After 2 h of RAH treatment, salicylic acid, and resveratrol-3-O-sulfate were identified as the major metabolites of RAH in the mouse plasma. This observation indicated that RAH is capable of rapid releasing resveratrol and aspirin after incorporation into intestine enterocyte, and the released resveratrol in the intestine may be metabolized and reabsorbed into circulatory blood system later, which is supported by the presence of microbial-derived metabolite, dihydro-resveratrol, in the mouse feces, and dihydroresveratrol conjugates in the mouse urine [68] . Further pharmacokinetic and distribution studies of RAH are needed to investigate the effect of structure modification on the metabolic rate and fate as well as biological activities of resveratrol.
Bioactivities of the metabolites of resveratrol and pterostilbene
Taken together, resveratrol is rapidly metabolized. However, limited information is available regarding the possible benefit of resveratrol metabolites. Based on current literature, sulfated conjugates partly maintain their bioactivity, but it seems that their activity decreases as the degree of sulfation increases [70] [71] [72] . Interestingly, resveratrol-3-O-sulfate, in contrast to unconjugated resveratrol, was found to exert pronounced anti-estrogen activity in a yeast-hybrid system with a marked preference for the human estrogen receptors a and b [73] . Resveratrol-3-O-sulfate also exhibits quinone reductase 1 inducing, DPPH free radical scavenging, and colon cancer cell proliferation-inhibiting activities [64, 71, 74, 75] . Furthermore, cardioprotective effects of resveratrol on diabetic heart of rats was partly attributed by the accumulation of resveratrol-3-Osulfate and resveratrol-3-O-glucuronide in the myocardial tissue [76] . Conversely, pinostilbene as a major metabolite of pterostilbene showed similar inhibitory effects on the growth of human colon cancer cells as pterostilbene, and these effects were associated with modulation of multiple key cellular proteins related with cell cycle arrest and cellular apoptosis [55] .
Pharmacokinetics of resveratrol and pterostilbene
Pharmacokinetics studies of resveratrol have been well established in animals and in humans, and it appears that different administration routes, doses, and patterns may result in discrepancies between data. Comparison of pharmacokinetics between resveratrol and pterostilbene were also carried out, which were significant for revealing and explaining the pharmacological similarities and differences between them.
Pharmacokinetics of resveratrol in humans
Impact of administration routes on the pharmacokinetics of resveratrol.
To comprehensively investigate the bioavailability of resveratrol, 14 
C-labeled resveratrol was administered orally and intravenously
BioFactors to six and five healthy subjects with doses of 25 and 0.2 mg, respectively [47] . Measurement of the urinary excretion data indicated a high absorption rate (at least 70%) after oral consumption of resveratrol, with the recovery of total radioactivity ranged from 53.4 to 84.9% in urine after oral intake. However, the bioavailability of resveratrol itself is close to zero due to the rapid and extensive biotransformation resulting in only trace amount of unchanged resveratrol in the systemic circulation, and a fairly high (maximum 2 lM) level of resveratrol metabolites after the 25 mg oral dose. The peak plasma total radioactivity was reached 1 h after oral intake and a second peak was observed at around 6 h post-dose, which likely resulted from the enteric recirculation of conjugate metabolites by reabsorption after intestinal hydrolysis. Similar with oral administration, after intravenous injection, a high absorption rate was observed, with the recovery of total radioactivity ranged from 42.3 to 83.2% in urine; while no second peak in any of five subjects was observed, after an intravenous injection of 0.2 mg dose, there was a rapid decrease of the plasma concentrations of total radioactivity over the first 1 h, indicating a rapid and extensive distribution phase. Moreover, a majority of resveratrol and its metabolites may bind with proteins and tissues before reaching the liver and being included in the enterohepatic cycle, indicating only a small amount of resveratrol goes to the enterohepatic cycle, which made the potential second peak hard to be detected. Nevertheless, the half-life times of plasma total radioactivity were similar after both routes of administration, with a half-time of 9.2 h after oral administration and 11.4 h after intravenous injection, and plasma concentrations decreased in a parallel, exponential manner of the 72 h study period.
Impact of doses on the pharmacokinetics of resveratrol.
Plasma concentration of the unchanged resveratrol was dependent on dosages ingested. Even analytical methods with low limit of quantification at the ng/mL level were established for the determination of plasma resveratrol, when the resveratrol was administered through consumption of wine or juices, the unchanged resveratrol was either not detectable at all or present in very low concentrations in plasma [77] . Oral dose of $25 mg of resveratrol was applied in several human studies for investigating of the bioavailability and kinetics of resveratrol in humans, which resulted in plasma concentration for unchanged resveratrol to range from 1 to 5 ng/mL [47, 78, 79] . Administration of higher doses (up to 5 g) led to the increase of unchanged resveratrol of up to 530 ng/mL. A phase I doseescalation (single doses of 0.5, 1, 2.5, or 5 g) pharmacokinetic study of resveratrol was conducted in a population of 40 healthy volunteers [80] . Resveratrol can be rapidly absorbed, yielding peak plasma concentration (C max ) between 0.83 and 1.5 h post-dose. The mean average concentration (C av ) and C max of the unchanged resveratrol across the four dose levels ranged from 8.4 to 52 ng/mL (0.04-0.23 lM) and from 73 to 539 ng/mL (0.3-2.4 lM), respectively. The three resveratrol conjugates (two monoglucuronides and a resveratrol-3-Osulfate) exceeded those of their progenitor molecule by 2-to 20-fold, as resveratrol-3-O-sulfate displayed the highest C av and C max concentrations, which ranged from 172 to 1,089 ng/ mL (0.56-3.5 lM) and 1,135 to 4294 ng/mL (3.7-14 lM), respectively. The equivalent values determined for the two glucuronides are 51-344 ng/mL (0.13-0.85 lM) and 370 to 1735 ng/mL (0.92-4.3 lM), respectively. The corresponding concentrations of resveratrol-3-O-sulfate exceeded that of unchanged resveratrol by 18-to 20-fold. The plasma half-lives of those three resveratrol conjugates were similar to that of the unchanged resveratrol (2.9-8.9 h). In urine, the free form of resveratrol was mainly excreted during the initial 4 h. In feces, only traces of resveratrol metabolites were detected. This study demonstrated that even after a high-dose resveratrol challenge, only a trace amount of the unchanged resveratrol was present in the plasma.
Impact of treatment regimens on the pharmacokinetics of resveratrol
A single-center, double-blind, randomized, placebo-controlled study was performed by Almeida et al. [79] to investigate the multiple-dose pharmacokinetics of resveratrol in healthy adults. Four groups of 10 healthy young adult volunteers (5 males and 5 females) were studied over 48 h. In each group, 2 volunteers (1 male and 1 female) were randomized to receive the placebo and the remaining 8 volunteers received resveratrol of 25, 50, 100, or 150 mg, 6 times per day (4 h interval), 13 doses in total. Comparable with most previous studies, C max were reached 0.8-1.5 h post-dose. The half-life time of resveratrol was prolonged from 1 to 3 h following single-administration to 2-5 h following repeated-doses. Following repeated-administration of resveratrol 25, 50, 100, or 150 mg at a very short interval (4 h), the degree of observed accumulation was not significant, with mean accumulation ratios ranging from 1.9 (resveratrol 100 mg) to 5.2 (resveratrol 50 mg). Despite the relatively short interval, the residual plasma concentrations (C min ) of resveratrol were below the LLOQ following most 25 mg doses, and $1, 3, and 10 ng/mL following 50, 100, and 150 mg, respectively. Interestingly, diurnal variation was observed for the first time in humans, and C min levels were peaked in the morning and tended to decrease throughout the day, being the lowest during the night. In a separate study [81] , 200 mg resveratrol was administrated to young and elderly subjects thrice-daily for eight doses, and results from this study suggested that resveratrol was rapidly cleared following multiple-doses, and its kinetic profile was independent of age and gender.
To investigate the steady-state pharmacokinetics and tolerability of resveratrol, a steady-state 12 h pharmacokinetics of resveratrol 2,000 mg twice daily were studied with a standard breakfast, a high-fat breakfast, quercetin 500 mg twice daily, and 5% alcohol 100 mL [82] . Besides frequent mild diarrhea, 2,000 mg resveratrol challenge resulted in adequate exposure and was well tolerated by healthy subjects. The mean area under the plasma concentration-time curve from 0 to 12 h (AUC 12 ) and C max of resveratrol were 3,558 ngÁh/mL and 1,274 ng/mL, respectively, after the standard breakfast, co-administration of a high-fat breakfast decreased and delayed the absorption of resveratrol, the AUC and C max were decreased by 45 and 46%, respectively, and the t max was prolonged to 5 h from 3 h, which demonstrate that food has an important impact on the pharmacokinetics and systemic exposure of resveratrol. Coadministration of 500 mg of quercetin twice per day and 100 mL of 5% alcohol did not influence the pharmacokinetics of resveratrol.
In a clinical trial study with 40 subjects [30] , volunteers ingested resveratrol at 0.4, 1.0, 2.5, or 5.0 g daily for 29 days. Consistent with the single dose study previously reported [80] , resveratrol-4 0 -O-glucuronide, resveratrol-3-O-glucuronide, and resveratrol-3-O-sulfate were identified as the major plasma metabolites, with maximal plasma levels and areas under the concentration versus time curve for the metabolites dramatically exceeded those for resveratrol. In the case of areas under concentration versus time curve, it increased by 20.3-fold.
Results from this study suggested that repeated administration of high doses of resveratrol generated micromolar concentrations of parent and much higher levels of glucuronide and sulfate conjugates in the plasma.
Compared with extensive pharmacokinetic studies of resveratrol in humans, no pharmacokinetic investigations of pterostilbene have been performed in humans yet, further studies are warranted.
Comparison of the pharmacokinetics of resveratrol and pterostilbene in rodents
Oral bioavailability of small molecular drugs is generally believed to be dependent on their aqueous solubility, membrane permeability, and metabolic stability [83] . Both resveratrol and pterostilbene possess poor aqueous solubility [84] [85] [86] . To investigate the impact of aqueous solubility on the pharmacokinetics of resveratrol and pterostilbene, water soluble intravenous, and oral formulations of resveratrol were prepared with hydroxypropyl-b-cyclodextrin (HP-b-CD) and methylatedb-cyclodextrin (RM-b-CD), respectively [84] . Water soluble pterostilbene solution was prepared with HP-b-CD [86] . Experiments were carried out in Sprague-Dawley rats, resveratrol was eliminated rapidly at all tested doses (5, 10, and 25 mg/kg) regardless of formulation types, with non-linear elimination occurring at the dose of 25 mg/kg. RM-b-CD significantly increased the C max of orally administered resveratrol; however, it did not increase the oral bioavailability in comparison with carboxymethyl cellulose suspension. Moreover, the oral bioavailability remained unchanged among all tested doses (15, 25 , and 50 mg/kg), indicating that aqueous solubility barrier might affect the velocity but will not improve the absorption of resveratrol. Furthermore, dose manipulation (up to 50 mg/kg) did not show significant impact on the oral bioavailability of resveratrol [84] . Contrary to resveratrol, doseescalation of pterostilbene led to about a 2-fold decline in clearance at the dose of 25 mg/kg and about a 2-fold increase in bioavailability at the dose of 60 mg/kg, and aqueous solubility was identified as a barrier to the oral bioavailability of pterostilbene [86] . Further pharmacokinetic comparison studies were carried out by intravenous administration of resveratrol or pterostilbene at a dose of 10 mg/kg, and oral administration of suspension or solution of resveratrol or pterostilbene at a dose of 15 mg/kg, respectively [84, 86] . Statistical comparison of the major pharmacokinetic parameters between resveratrol and pterostilbene showed that both of them had similar values of apparent volume of distribution of the central compartment on intravenous injection; however, the elimination rate and clearance of resveratrol was significantly faster than that of pterostilbene, and the mean transition time of resveratrol was significantly shorter than that of pterostilbene. Obviously, the metabolic stability of resveratrol was much lower than pterostilbene, and the superior metabolic stability of pterostilbene could be explained by the dimethyl ether structure, which endues a lower susceptibility to be conjugated with glucuronic and/or sulfonic acid. After oral administration of suspension (15 mg/kg), pterostilbene tended to have lower C max but higher plasma exposure (AUC). Furthermore, when solution formulation (15 mg/kg) was given, pterostilbene had lower C max but its plasma exposure was about 5 times higher and longer than resveratrol. Clearly, when an optimized formulation was applied, pterostilbene presented significantly superior pharmacokinetic properties than resveratrol.
Comments and conclusions
The objective of this review was to compare the available literature information about the metabolism and pharmacokinetics of resveratrol and pterostilbene. Although the information is collected mostly from different studies, which were carried out in different models with different administration routes and doses, the data provided important information and raised some interesting perspectives. First, both resveratrol and pterostilbene can be rapidly absorbed and metabolized, mainly in their glucuronidated and sulfated forms, then excreted in urine. Structurally, as a dimethyl ether derivative of resveratrol, pterostilbene provides only a single hydroxyl group for conjugation reactions. This makes pterostilbene a less favorable substrate of glucuronidase and sulfatase, which further lead to a better metabolic stability of pterostilbene than resveratrol. Secondly, besides the phase II metabolic enzymes, the role of gut microbiota in metabolizing resveratrol and pterostilbene should not be ignored. Thirdly, the biological activities of the metabolites of resveratrol and pterostilbene are largely unknown, which will be an important topic for future studies. Last but not least, comparison pharmacokinetics of resveratrol and pterostilbene in animals revealed that pterostilbene exhibited a superior pharmacokinetic profile than that of resveratrol, which could be a good explanation of why in vitro and/or in vivo pharmacological activities of pterostilbene are usually found to be superior than that of resveratrol. However, comparison of pharmacokinetic studies between resveratrol and pterostilbene in humans still remain unexplored. Further research into the metabolism and pharmacokinetics of resveratrol and pterostilbene as well as other resveratrol derivatives is needed to validate, confirm, and compare their safety and therapeutic properties.
